Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: Implications for the pathogenesis of chronic allograft nephropathy

Journal of Immunology

Volumn 167, Issue 12, 2001, Pages 7199-7206

  Baker, R J ^a   Hernandez Fuentes, M P ^a   Brookes, P A ^a   Chaudhry, A N ^a   Cook, H T ^a   Lechler, R I ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 5;

ADULT; ALLOGRAFT; ALLOIMMUNITY; ANTIGEN RECOGNITION; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; GRAFT FAILURE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; KIDNEY ALLOGRAFT; KIDNEY DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RECIPIENT; T LYMPHOCYTE;

EID: 0035893012     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.12.7199     Document Type: Article

References (62)

1. The role of HLA in renal transplantation
2. Risk factors for chronic rejection in renal allograft recipients
3. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens
4. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: A pilot study
5. Clinically stable human renal allografts contain histological and RNA-based findings that correlate with deteriorating graft function
6. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection
7. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection
8. Indirect presentation of MHC antigens in transplantation
9. Acquired immune tolerance to cadaveric renal allografts: A study of three patients treated with total lymphoid irradiation
10. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation
11. Renal transplant patients treated with total lymphoid irradiation show specific unresponsiveness to donor antigens the mixed leukocyte reaction (MLR)
12. Detection of donor-specific hyporesponsiveness following late failure of human renal allografts
13. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity
14. Donor-specific hyporeactivity after liver transplantation: Prominent decreases in donor-specific cytotoxic T lymphocyte precursor frequencies independent of changes in helper T lymphocyte precursor frequencies or suppressor cell activity
15. Evidence that human cardiac allograft acceptance is associated with a decrease in donor-reactive helper T lymphocytes
16. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans
17. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction
18. Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection
19. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts
20. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome
21. T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice
22. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice
23. The Banff 97 working classification of renal allograft pathology
24. Microdroplet assay of human serum cytotoxins
25. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation
26. Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB 1, DRB3, DRB4, DRB5, and DQB 1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP)
27. A rapid limiting dilution assay for measuring frequencies of alloreactive, interleukin-2-producing T cells in humans
28. Optimizing a limiting dilution culture system for quantifying the frequency of interleukin-2-producing alloreactive T helper lymphocytes
29. Optimizing limiting dilution assays: Frequency and "ability" measurements of haemopoietic progenitor cells
30. Human anti-porcine xenogeneic T cell response: Evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition
31. Likelihood-based methods for bias reduction in limiting dilution assays
32. Limiting dilution analysis of helper T-cell function
33. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins
34. The Th1/Th2 paradigm and the allograft response
35. On histo-compatibility barriers. Th1 to Th2 immune deviation, and the nature of the allograft responses
36. Clinical application of molecular biology: A study of allograft rejection with polymerase chain reaction
37. Longitudinal study of the frequency of cytotoxic T cell precursors in kidney allograft recipients
38. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells
39. Clinical significance of selective decline of donor-reactive IL-2-producing T lymphocytes after renal transplantation
40. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immuno-suppressive therapy can be safely reduced
41. Immune-activation gene expression in clinically stable renal allograft biopsies: Molecular evidence for subclinical rejection
42. + T cells
43. Reversal of in vitro T cell clonal anergy by IL-2 stimulation
44. The role of T-cell anergy in the maintenance of donor-specific hyporesponsiveness in renal transplant recipients
45. The role of the allograft in the induction of donor-specific T cell hyporesponsiveness
46. Clonotype analysis of human alloreactive T cells: A novel approach to studying peripheral tolerance in a transplant recipient
47. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient
48. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance
49. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
50. Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo
51. Two levels of help for B cell alloantibody production
52. Indirect T cell allorecognition of donor antigens contributes to the rejection of vascularized kidney allografts
53. + T-cell dependent antibody-mediated graft rejection
54. Postoperative production of anti-donor antibody and chronic rejection in renal transplantation
55. Peritubular capillaries in chronic renal allograft rejection: A quantitative ultrastructural study
56. Capillary deposition of C4d complement fragment and early renal graft loss
57. Electron-microscopic peritubular capillary lesion is a specific and useful diagnostic indicator for chronic rejection of renal allografts showing less specific morphologic lesions in the cyclosporine era
58. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries
59. Pretransplant frequency of donor-specific, IFN-γ-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes
60. Trans vivo analysis of human delayed-type hypersen-sitivity reactivity
61. Human allograft acceptance is associated with immune regulation
62. Optimal analysis of composite cytokine responses during alloreactivity